Table 2.
Estimated mean difference in 1- and 3-year change from baseline on composite Z score for the three intervention groups compared to the placebo group
| Groups | Estimated mean change from baseline (95% CI) | Estimated mean between-group difference in change from baseline (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusteda | ||||||
| vs. placebo | Raw P | Hochberg P | vs. placebo | Raw P | Hochberg P | ||
| 1-year ITT MAPT analysis (n = 483) | |||||||
| Positive plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | 0.1392 (0.0018; 0.2765) | 0.1917 (0.0136; 0.3699) | 0.0350 | 0.1049 | 0.1891 (0.0104; 0.3679) | 0.0381 | 0.1144 |
| Omega 3 alone | -0.0267 (-0.1555; 0.1022) | 0.0259 (-0.1458; 0.1976) | 0.7669 | 0.7669 | 0.0074 (-0.1676; 0.1824) | 0.9338 | 0.9338 |
| Multidomain plus placebo | 0.0835 (-0.0490; 0.2160) | 0.1361 (-0.0383; 0.3106) | 0.1260 | 0.2519 | 0.1113 (-0.0649; 0.2874) | 0.2153 | 0.4306 |
| Placebo | -0.0526 (-0.1661; 0.0609) | - | - | - | - | - | - |
| Negative plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.0059 (-0.0884; 0.0765) | 0.0241 (-0.1007; 0.1488) | 0.7050 | 0.9950 | 0.0199 (-0.1066; 0.1463) | 0.7578 | 0.9306 |
| Omega 3 alone | -0.0296 (-0.1240; 0.0648) | 0.0004 (-0.1325; 0.1334) | 0.9950 | 0.9950 | 0.0135 (-0.1584; 0.1879) | 0.8445 | 0.9306 |
| Multidomain plus placebo | -0.0176 (-0.1058; 0.0707) | 0.0124 (-0.1162; 0.1411) | 0.8494 | 0.9950 | 0.0058 (-0.1244; 0.1360) | 0.9306 | 0.9306 |
| Placebo | -0.0300 (-0.1236; 0.0636) | - | - | - | - | - | - |
| 1-year per-protocol MAPT analysis (n = 457) | |||||||
| Positive plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | 0.1880 (0.0440; 0.3319) | 0.2435 (0.0582; 0.4287) | 0.0101 | 0.0302 | 0.2424 (0.0571; 0.4276) | 0.0104 | 0.0313 |
| Omega 3 alone | -0.0264 (-0.1564; 0.1036) | 0.0291 (-0.1455; 0.2037) | 0.7437 | 0.7437 | 0.0070 (-0.1705; 0.1845) | 0.9383 | 0.9383 |
| Multidomain plus placebo | 0.0846 (-0.0527; 0.2220) | 0.1402 (-0.0400; 0.3203) | 0.1270 | 0.2540 | 0.1132 (-0.0684; 0.2949) | 0.2214 | 0.4428 |
| Placebo | -0.0555 (-0.1721; 0.0611) | - | - | - | - | - | - |
| Negative plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.0022 (-0.0894; 0.0850) | 0.0288 (-0.1002; 0.1578) | 0.6611 | 0.8971 | 0.0229 (-0.1073; 0.1532) | 0.7298 | 0.9902 |
| Omega 3 alone | -0.0399 (-0.1363; 0.0565) | -0.0089 (-0.1443; 0.1265) | 0.8971 | 0.8971 | -0.0009 (-0.1375; 0.1358) | 0.9902 | 0.9902 |
| Multidomain plus placebo | -0.0115 (-0.1046; 0.0816) | 0.0195 (-0.1136; 0.1526) | 0.7735 | 0.8971 | 0.0178 (-0.1165; 0.1522) | 0.7947 | 0.9902 |
| Placebo | -0.0310 (0.1261; 0.0641) | - | - | - | - | - | - |
| 3-year ITT MAPT analysis (n = 483) | |||||||
| Positive plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.0931 (-0.2959; 0.1098) | 0.2818 (0.0190; 0.5446) | 0.0357 | 0.1071 | 0.3030 (0.0420; 0.5640) | 0.0230 | 0.0690 |
| Omega 3 alone | -0.2530 (-0.4443; -0.0616) | 0.1219 (-0.1322; 0.3760) | 0.3461 | 0.3461 | 0.1257 (-0.1305; 0.3820) | 0.3353 | 0.3353 |
| Multidomain plus placebo | -0.2051 (-0.3972; -0.0130) | 0.1698 (-0.0849; 0.4244) | 0.1907 | 0.3461 | 0.1399 (-0.1148; 0.3946) | 0.2808 | 0.3353 |
| Placebo | -0.3749 (-0.5420; -0.2077) | - | - | - | - | - | - |
| Negative plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.1527 (-0.2729; -0.0325) | -0.0075 (-0.1890; 0.1740) | 0.9352 | 0.9352 | -0.0037 (-0.1861; 0.1787) | 0.9684 | 0.9684 |
| Omega 3 alone | -0.1173 (-0.2550; 0.0203) | 0.0278 (-0.1657; 0.2213) | 0.7775 | 0.9352 | 0.0194 (-0.1748; 0.2136) | 0.8443 | 0.9684 |
| Multidomain plus placebo | -0.1356 (-0.2663; -0.0049) | 0.0096 (-0.1791; 0.1982) | 0.9206 | 0.9352 | 0.0180 (-0.1710; 0.2071) | 0.8512 | 0.9684 |
| Placebo | -0.1452 (-0.2812; -0.0091) | - | - | - | - | - | - |
| 3-year per-protocol MAPT analysis (n = 457) | |||||||
| Positive plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.0298 (-0.2415; 0.1820) | 0.3490 (0.0769; 0.6210) | 0.0121 | 0.0362 | 0.3747 (0.1055; 0.6439) | 0.0065 | 0.0195 |
| Omega 3 alone | -0.2534 (-0.4461; -0.0607) | 0.1253 (-0.1322; 0.3828) | 0.3392 | 0.3392 | 0.1254 (-0.1334; 0.3842) | 0.3413 | 0.3413 |
| Multidomain plus placebo | -0.2158 (-0.4142; -0.0173) | 0.1630 (-0.0988; 0.4248) | 0.2217 | 0.3392 | 0.1297 (-0.1317; 0.3911) | 0.3299 | 0.3413 |
| Placebo | -0.3787 (-0.5495; -0.2080) | - | - | - | - | - | - |
| Negative plasma Aβ42/40 | |||||||
| Multidomain plus omega 3 | -0.1452 (-0.2725; -0.0179) | 0.0047 (-0.1830; 0.1924) | 0.9605 | 0.9605 | 0.0051 (-0.1827; 0.1930) | 0.9572 | 0.9572 |
| Omega 3 alone | -0.1284 (-0.2683; 0.0116) | 0.0216 (-0.1750; 0.2181) | 0.8294 | 0.9605 | 0.0068 (-0.1897; 0.2033) | 0.9457 | 0.9572 |
| Multidomain plus placebo | -0.1321 (-0.2694; 0.0051) | 0.0178 (-0.1768; 0.2123) | 0.8576 | 0.9605 | 0.0289 (-0.1656; 0.2234) | 0.7703 | 0.9572 |
| Placebo | -0.1499 (-0.2878; -0.0120) | - | - | - | - | - | - |
ITT intention-to-treat, MAPT Multidomain Alzheimer Prevention Trial
aAnalysis adjusted for age, sex, level of education, APOE ε4 genotype, and clinical dementia rating global score